Special Issue

Diagnosis and Treatment of Biofilm-Related Infections

Message from the Guest Editor

Microbial biofilms have been recognized to contribute to the pathogenesis of the majority of clinical infections, particularly of chronic infections. Even if production of biofilm is often associated with adhesion to inert or biotic surfaces, such as implant devices, nowadays we know that bacteria are able to form free aggregates with characteristics similar to those of adhered biofilm. The biofilm matrix, as well as the low metabolic rate, protects bacteria from the activity of the host immune system and from antibiotics. As a consequence, biofilm-related infections are persistent ones, are rarely effectively counteracted by the immune system, and poorly respond to antimicrobial treatments, representing a hard challenge for clinicians and microbiologists. Moreover, treatment of these infections is often long and may include prolonged hospitalization, thus heavily affecting the quality of life of patients. This Special Issue focuses on diagnosis and treatment of biofilm-related infections and will consist of 10–15 manuscripts, including original research articles, reviews and opinion papers.

Guest Editor

Dr. Elena De Vecchi
IRCCS Istituto Ortopedico Galeazzidisabled, Milan, Italy

Deadline for manuscript submissions

closed (30 September 2022)

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/89292

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI